Natera Inc (NTRA)
Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell
$376.00
Buy
$449.00
$5.98 (+1.52%)
Prices updated at 19 Oct 2026, 10:48 EDT
| Prices minimum 15 mins delay
Prices in USD
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 1,697m | 2,306m | |
| 1,023m | 1,493m | |
| -222m | -310m | |
| -13.10 | -13.44 | |
| -190m | -208m | |
| -148m | -221m | |
| Sales, General and administrative | 841m | 1,177m |
| Interest expenses | 11m | 4m |
| Provision for income taxes | 695,000 | -60m |
| Operating expenses | 1,245m | 1,803m |
| Income before taxes | -190m | -268m |
| Net income available to common shareholders | -190m | -208m |
| -1.53 | -1.52 | |
| Net interest income | 33m | 42m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.53 | -1.52 |
| Free cash flow per share | -0.3589 | 0.6931 |
| Book value/share | 6.6231 | 8.9639 |
| Debt equity ratio | 0.080798 | 0.069185 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 1,376m | 1,497m |
| Current liabilities | 344m | 441m |
| Total capital | 1,195m | 1,712m |
| Total debt | 187m | 214m |
| Total equity | 1,195m | 1,712m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 1,661m | 2,398m |
| Total liabilities | - | - |
| Cash and cash equivalents | 946m | 1,076m |
| Common stock | 133m | 140m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 642m | 946m |
| Cash dividends paid | - | - |
| 59m | 76m | |
| Investments (gains) losses | 138m | -132m |
| 946m | 1,076m | |
| Net income | - | - |
| 136m | 215m | |
| -77m | -139m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
